HopeStage
Back to all studies
TerminatedNCT00374543

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolarity

Medication studyAges 18–75United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 75 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateFebruary 2006
Recruitment status
Terminated
Enrollment listed in the registry
3
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT00374543
Official title
Show the full official title

Ziprasidone for the Treatment of Generalized Anxiety Comorbidity in Patients With Bipolar Disorder

Recruitment & locations

Terminated

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Ziprasidone and Placebo.

Who can participate?

Listed age limits: 18 years to 75 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies